Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00444535
Status:
COMPLETED
Last Update Posted:
2021-10-25
First Post:
2007-03-06
Brief Title:
Lapatinib and Bevacizumab for Metastatic Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Neoplasms Breast |
Keywords:
| Name | View |
|---|---|
| Pagets disease | View |
| VEGF | View |
| Tyrosine kinase | View |
| ErbB2 | View |
| Her2-neu | View |
| metastatic breast cancer | View |
| EGFR | View |
| ErbB1 | View |
| bevacizumab | View |
| lapatinib | View |
| breast carcinoma | View |
| breast cancer | View |
| breast lump | View |
| breast cancer positive for human epidermal growth factor receptor 2 HER2 | View |
| HER2 positive metastatic breast cancer | View |
| breast cancer progression | View |
| estrogen-receptor ER positive breast cancer | View |